Health Products Regulatory Authority

Summary of Product Characteristics

1 NAME OF THE VETERINARY MEDICINAL PRODUCT

Gleptosil 200 mg/ml Solution for Injection

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substance:

Iron 200 mg/ml (as gleptoferron complex 532.6 mg/ml)

Excipients:

Phenol 5 mg/ml

For the full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM

Solution for injection.

A dark brown, slightly viscous, sterile, colloidal, aqueous solution.

4 CLINICAL PARTICULARS

4.1 Target Species

Neonatal pigs.

4.2 Indications for use, specifying the target species

Neonatal pigs:

For the prevention and treatment of iron deficiency anaemia.

4.3 Contraindications

None.

4.4 Special warnings for each target species

None.

22 November 2019 CRN009DV5 Page 1 of 4

4.5 Special precautions for use

Special precautions for use in animals

Normal aseptic injection techniques should be practised.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Care should be taken to avoid accidental self injection. In the event of accidental self injection seek medical advice. Wash hands after use.

Other precautions

The sachet should not be opened until the product is required for use.

Avoid the introduction of contamination during use.

4.6 Adverse reactions (frequency and seriousness)

There are normally no undesirable side effects associated with the use of the product. Its use does not result in permanent staining of the injected muscle tissue.

4.7 Use during pregnancy, lactation or lay

Not applicable.

4.8 Interaction with other medicinal products and other forms of interactions

There are no known interactions between the product and other medicaments. There are no known other forms of interaction. Do not mix with other products prior to administration.

4.9 Amounts to be administered and administration route

Swab the septum before use. The product is administered as a single 1 mL (200 mg iron) dose by deep intramuscular injection into the hind limb midway between the stifle joint and the base of the tail. Injections should be administered as follows: For the prevention of iron deficiency anaemia: not later than the third day of life.

For the treatment of iron deficiency anaemia: at the onset of clinical anaemia, normally within the first three weeks of life. For 100 ml collapsible vial: as the stopper of the vial cannot be broached more than 4 times, the use of automatic syringe equipment is recommended.

For 100 & 250 ml multilayer plastic vials: as the vial cannot be broached more than 20 times, use of automatic syringe equipment is recommended.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Overdosage with the product is unlikely to result in signs of intoxication.

4.11 Withdrawal period(s)

Meat and offal: Zero days.

5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group:

Antianemic preparations, Iron preparations, Iron trivalent, parenteral preparations.

ATC vet code:QB03AC91.

5.1 Pharmacodynamic properties

Injectable iron-carbohydrate complexes are established haematinic agents in veterinary medicine. Following intramuscular injection, the complex is absorbed and metabolised to release the iron for utilisation and/or storage in accordance with the

22 November 2019 CRN009DV5 Page 2 of 4

Health Products Regulatory Authority

nutritional status of the animal. In iron deficient states, the iron is utilised for the synthesis of haemoglobin and other iron-containing molecules. Excess iron is stored principally in the liver.

5.2 Pharmacokinetic particulars

Absorption of the product has been shown to be rapid. Over 95% of the administered iron (1mL/200 mg iron administered at three days of age) was absorbed by 24 hours after injection. Use of the product does not result in permanent staining of the injected muscle tissue.

Environmental properties

Not applicable.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Phenol Water for injections

6.2 Major incompatibilities

None known.

6.3 Shelf-life

Shelf life of the veterinary medicinal product as packaged for sale in 100 ml collapsible vial: 2 years. Shelf-life of the veterinary medicinal product as packaged for sale in 100 & 250 ml multilayer plastic vials: 3 years. Shelf-life after opening the immediate packaging: 28 days

6.4 Special precautions for storage

Do not store above 25°C. Protect from light.

6.5 Nature and composition of immediate packaging

100 ml clear colourless low-density polyethylene collapsible bottles with grey chlorobutyl rubber bung with aluminium overseal.

100 & 250 ml translucent multi layer plastic (polypropylene/adhesive/ ethylene vinyl alcohol layer/adhesive/ polypropylene) vials with fluoro coated bromobutyl rubber stopper.

Pack sizes

Cardboard box containing 1 vial of 100 ml collapsible bottle Cardboard box containing 1 vial of 100 ml multi layer plastic vial Cardboard box containing 1 vial of 250 ml multi layer plastic vial Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

Ceva Santé Animale 10, avenue de La Ballastière 33500 Libourne France

22 November 2019 CRN009DV5 Page 3 of 4

8 MARKETING AUTHORISATION NUMBER(S)

VPA10815/027/001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 01 October 1989 Date of last renewal: 30 September 2009

10 DATE OF REVISION OF THE TEXT

November 2019

22 November 2019 CRN009DV5 Page 4 of 4